Cover storyCDMO Trends 2026: What’s Driving Mergers And Acquisitions
CDMO trends 2026 show a structural consolidation wave — bigger deals, sharper specialization, and rising onshoring pressure reshaping manufacturing.
Cover storyCDMO trends 2026 show a structural consolidation wave — bigger deals, sharper specialization, and rising onshoring pressure reshaping manufacturing.

Cipla's Pithampur site received a seven-observation Form 483 after a USFDA follow-up inspection concluding August 25, 2026.

Ascendis Pharma presents 104-week ApproaCH Trial data for navepegritide at ISDS 2026, ahead of an anticipated EMA decision in Q4 2026.

FDA approves Tivicay PD oral suspension for HIV-infected neonates from birth, backed by IMPAACT 2023 pharmacokinetic data.

FDA's infectious disease accelerated approval tracker shows two overdue PMR deadlines, Benznidazole (May 2026) and Arikayce (June 2024), with Hepcludex carrying a 2034 completion target.
Latest edition

Sep 28
Feb 03From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.








Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
